DB 1418
Alternative Names: DB-1418Latest Information Update: 19 Sep 2024
At a glance
- Originator Duality Biologics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Sep 2024 DB 1418 is available for licensing as of 02 Sep 2024. https://www.dualitybiologics.com/partnership.html
- 02 Sep 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to September 2024 (Duality Biologics pipeline, September 2024)